Clinical Trials

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06496178 2026-03-18

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Phase 3 Recruiting

500 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06589804 2026-03-18

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

158 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06806852 2026-03-18

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

90 enrolled

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07156227 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

39 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

40 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT05120947 2026-03-17

HART-HN

Phase NA Completed

18 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT05136196 2026-03-17

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Phase 2 Recruiting

150 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05539638 2026-03-17

The Role of Circulating Tumour DNA in Head and Neck Cancer

Recruiting

250 enrolled

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06993844 2026-03-17

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

233 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07115043 2026-03-17

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

60 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03485209 2026-03-16

innovaTV 207

Phase 2 Active not recruiting

352 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04042935 2026-03-16

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

Phase 1 Completed

5 enrolled

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

DermatologicHead & NeckThoracic

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06332092 2026-03-16

HNSCC

Phase 2 Active not recruiting

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01810913 2026-03-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04892173 2026-03-13

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Phase 3 Recruiting

500 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT06030440 2026-03-13

DIREKHT2

Phase 2/3 Recruiting

508 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07219212 2026-03-13

LUMIRAY

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07471009 2026-03-13

SPAR

Not yet recruiting

120 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03386357 2026-03-12

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Terminated

115 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT05176483 2026-03-12

STELLAR-002

GastrointestinalGenitourinaryHead & NeckThoracic

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06211335 2026-03-12

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06947668 2026-03-12

DoIT_Neck

Recruiting

250 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03313804 2026-03-11

Priming Immunotherapy in Advanced Disease With Radiation

76 enrolled 9 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04696744 2026-03-11

CTCO

Completed

12 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplastic Cells, Circulating, Oropharyngeal Neoplasms

NCT07465276 2026-03-11

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT00939627 2026-03-10

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

55 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT03370276 2026-03-10

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 1/2 Completed

95 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

NCT07229313 2026-03-10

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors